The Food and Drug Administration issued a complete response letter to Arena Pharmaceuticals for its obesity drug Lorqess (lorcaserin) on Oct. 22, a move most analysts thought was inevitable after an advisory committee voted 9-5 against approval in September.
Over the next 40 years, the total prevalence of diabetes in the United States is expected to increase from its current level of about 1 in 10 adults to as many as 1 in 3 by 2050.
The Food and Drug Administration has approved trastuzumab, along with chemotherapy, to treat metastatic HER2-positive gastric cancers in people who have not been previously treated for metastatic disease.
Anorexia and bulimia can do measurable and likely irreversible damage to womens eyes, researchers in Greece have found.
ADELPHI, Md. (EGMN) The majority of a Food and Drug Administration advisory committee on Oct. 18 did not recommend changes in the way darbepoetin alfa is currently dosed for treating anemia in patients with chronic renal failure who are not on dialysis, based on the results of the TREAT (Trial to Reduce Cardiovascular Events with Aranesp Therapy) study.
Treatment for 6 weeks with teriparatide, a U.S.-approved drug that stimulates bone remodeling, led to significant, 1-year improvements in alveolar bone formation and clinical outcomes in a controlled, pilot study of 40 patients undergoing periodontal surgery.
The Food and Drug Administration is encouraging health care professionals to report any adverse events associated with over-the-counter products marketed to patients as chelation treatments for various diseases. These products have not been approved by the FDA for any indication and are potentially dangerous.
Women with fibromyalgia who participated in an 8-week yoga program reported significant improvements on measures of fibromyalgia symptoms and function, based on data from a pilot study of 53 women. The results were published online on Oct. 14 in the journal Pain.
